Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00372307

Enrollment

Registered

2006-09-06

Start date

2004-05-31

Completion date

2004-11-30

Last updated

2007-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo Vulgaris

Brief summary

Patients with vitiligo vulgaris are treated with Pimecrolimus twice a day during 6 months. After a baseline visit, patient returns for a control visit after 3 and 6 months of treatment. One reference lesion is clinically evaluated with pictures.

Interventions

DRUGApplication of pimecrolimus

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Years to No maximum

Healthy volunteers

Inclusion criteria

* Active or stable vitiligo vulgaris * lesions at head or neck + maximum 10% lesions at the rest of the body

Exclusion criteria

* Topica during last 2 weeks * Photo(chemo)therapy during last 4 weeks * Segmentary vitiligo

Design outcomes

Primary

Measure	Time frame
Repigmentation percentage of the reference lesion after 6 months.	—

Secondary

Measure	Time frame
Number of patients with repigmentation after 3 and 6 months.	—
Repigmentation percentage of the reference lesion after 3 months.	—
Adverse events (month 3 and 6).	—

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026